

**ARIC Manuscript Proposal #4145**

**PC Reviewed:** 10/11/22  
**SC Reviewed:** \_\_\_\_\_

**Status:** \_\_\_\_\_  
**Status:** \_\_\_\_\_

**Priority:** 2  
**Priority:** \_\_\_\_\_

**1.a. Full Title:** Preventative Potential of Hearing Loss Control on Dementia Risk

**b. Abbreviated Title (Length 26 characters):**

Fraction of dementia from hearing loss

**2. Writing Group:**

Writing group members:

Emily Ishak (First Author, manuscript)  
Emily Burg (First Author, manuscript)  
Jason R. Smith (First author, proposal)  
Pablo Martinez Amezcua  
Kening Jiang  
Danielle S. Powell  
Alison R. Huang  
Jonathan J. Suen  
A. Richey Sharrett  
James Russell Pike  
Josef Coresh  
Pamela L. Lutsey  
Nicholas S. Reed  
Jennifer A. Deal (Senior Author)  
Other ARIC authors/investigators welcome

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. JRS [**please confirm with your initials electronically or in writing**]

**First author:**

Name: Jason Smith  
Address: 2024 E. Monument St., Baltimore, MD 21205  
Phone: 919-265-3337  
E-mail: jsmit491@jhu.edu

**ARIC author** to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Jennifer A. Deal

Address: 2024 East Monument Street, Suite B-1008, Baltimore, MD 21205  
Phone: 410-955-1909  
Fax: 410-614-9625  
E-mail: jdeal1@jhu.edu

### **3. Timeline:**

Analysis and manuscript development will be completed in 12 months.

### **4. Rationale:**

Associations between hearing loss and elevated dementia risk have been consistently documented in observational studies.<sup>1</sup> In 2020, these data led the Lancet dementia commission to add hearing loss as a novel modifiable risk factor for dementia.<sup>2</sup>

The commission<sup>2</sup> was the first to estimate a population attributable fraction (PAF; the upper bound of the number of dementia cases that could potentially be prevented if hearing loss were eliminated entirely) of dementia from hearing loss (8%), and one recent study quantified a smaller PAF of 2%.<sup>3</sup> However, there are several limitations to their approaches. The use of a systematic review, for example, that included several studies leveraging subjective measures of hearing (i.e., self-reported hearing loss)<sup>4</sup> for the relative measure of association between hearing and dementia might have led to an underestimation among older adults<sup>5</sup> of the true preventative potential of hearing loss control on dementia risk. Without individual-level follow-up data, these prior studies also could not use PAF formulas that account for potential confounding in association measures,<sup>6,7</sup> which can also downwardly bias PAF estimates in the presence of positive confounding of the exposure-outcome association.<sup>8</sup>

To address this gap in the literature, we aim to provide the first estimate—to our knowledge—of the PAF of dementia from objectively measured hearing loss among a well-characterized biracial, community-based cohort of older adults with longitudinal, individual-level follow-up data.

### **5. Main Hypothesis/Study Questions:**

What is the proportion of dementia risk attributable to audiometric hearing loss? And does this vary by age and sex?

### **6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).**

#### **Study design and sample**

Our inclusion criteria will be all ARIC participants with race recorded at Visit 1 (1987-1989) as well as complete hearing data assessed at Visit 6 (2016-2017). For the primary analysis we will

exclude those with dementia diagnosis at Visit 5 and those with missing hearing and covariate data.

Given the expected minimal change in hearing between Visit 5 and 6, and to maximize the available follow-up data, the baseline for this analysis is Visit 5. In the primary analysis we will estimate longitudinal associations (hazard ratios and PAFs) between hearing loss and incident dementia at Visit 7. Data from Visit 8 will be incorporated as it becomes available.

### **Dementia diagnosis**

We will define dementia diagnosis through Visit 7/8 using the standardized ARIC algorithm.<sup>9,10</sup> The algorithm leverages: a) longitudinal cognitive data and complete neuropsychological battery data among participants attending clinic visits; b) supplemental cognitive data obtained outside clinic visits, including the six-item screener (SIS) of Alzheimer's disease 8 (AD8) from Visit 6 and Visit 7; and c) ICD-9/10 claims-based definitions for dementia from hospitalizations or death certificates (with onset date estimated as 6 months pre-hospitalization).

### **Hearing impairment**

Pure tone air conduction audiometry was conducted at Visit 6 at all 4 study sites in a sound-treated booth within a quiet room. If audiometry was collected at home or LTC visits, staff used portable audiometers. Pure tone audiometry is the reference-standard test to determine the faintest tones that a person can detect for a range of pitches. We will calculate a better-hearing ear, 4-frequency pure tone average (PTA) in decibels hearing level (dB HL) using audiometric thresholds at the speech frequencies of 0.5, 1, 2, and 4 kHz.

We will define hearing impairment at Visit 6 as PTA >25 dB HL and categorize PTAs using predefined clinical cut points (normal hearing,  $\leq 25$  dB; mild hearing loss, 26-40 dB; moderate or greater hearing loss, >40 dB). This parameterization is consistent with previous analyses in ARIC (e.g.<sup>11</sup>).

### **Covariates**

Demographic data from Visit 1 (1987-1989) will include date of birth (to derive age at Visit 5), sex, race/ethnicity, and education (< less than high school, high school or equivalent, > high school).

Clinical data will include *APOE*  $\epsilon 4$  carrier status (0 alleles versus 1+), self-reported smoking history (never, former, current smoker), body mass index (calculated as weight kilograms/height m<sup>2</sup>), diabetes (yes [fasting glucose  $\geq 126$  mg/dL or nonfasting glucose  $\geq 120$  mg/dL or self-reported physician diagnosis of diabetes or use of oral diabetes medication or use of insulin] versus no [not meeting criteria]), hypertension (yes [ $\geq 140/\geq 90$  mm Hg or use of antihypertension medication] versus no), self-reported prevalent stroke, and number of depressive symptoms (measured by the CES-D). All covariates were measured at Visit 5 and treated as time-invariant.

### **Statistical analysis**

To characterize the sample, we will first describe the prevalence of demographic and clinical characteristics by hearing loss category. We will use t-tests, Mann-Whitney *U* tests, and chi-squared tests to compare groups by number of impairments using two sided tests with alpha of 0.05.

For the main analysis we will first estimate the association between hearing loss and dementia using multivariable Cox proportional hazards regression models adjusted for demographic covariates. Using the confounder-adjusted hazard ratios, we will then estimate adjusted PAFs of dementia from hearing loss.<sup>6,7</sup>

$$PAF = pd \left( \frac{HR-1}{HR} \right)$$

Where *pd* is the prevalence of the *ith* level of hearing loss among dementia cases. This approach has been used in prior ARIC work (ARIC MS# 3965), however we will also consider alternative formulations of the PAF in subsequent analyses, if appropriate.

We will adjust for all demographic covariates outlined in the covariate section only in the primary analysis. To obtain 95% confidence intervals for the PAFs, we will use 5,000 bootstrapped samples.

In secondary analyses we will stratify models by age (<75 years, ≥ 75 years) and sex. We will also explore the potential impact of hearing aid use on dementia risk by estimating PAFs for dementia from no hearing aid use (reference group being hearing aid use).

### **Limitations and sensitivity analyses**

To examine the robustness of our primary models, we will consider a) additional adjustment of the primary models for health-related and clinical covariates (*APOE* carrier status, depressive symptoms, smoking status, prevalent stroke, hypertension, and diabetes), and b) imputation of missing hearing and covariate data using multiple imputation with chained equations. Given that hearing status might be associated with phone-based ascertainment of dementia diagnosis, we will explore this as a possible source of measurement bias.

All analyses will be conducted in R version 4.0.2 (R Foundation for Statistical Computing, 2020)

**7.a. Will the data be used for non-ARIC analysis or by a for-profit organization in this manuscript?** \_\_\_\_ Yes \_\_X\_\_ No

**b. If Yes, is the author aware that the current derived consent file ICTDER05 must be used to exclude persons with a value RES\_OTH and/or RES\_DNA = “ARIC only” and/or “Not for Profit” ?** \_\_\_\_ Yes \_\_\_\_ No

(The file ICTDER has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

**8.a. Will the DNA data be used in this manuscript?** \_\_\_\_ Yes \_\_X\_\_ No

**8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the current derived consent file ICTDER05 must be used to exclude those with value RES\_DNA = “No use/storage DNA”? \_\_\_\_ Yes \_\_\_\_ No**

**9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: <http://www.csc.unc.edu/aricproposals/dtSearch.html>**

☒ Yes ☐ No

**10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?**

#3577 Role of hearing impairment in cognitive decline and progression to dementia in older adults (Jennifer Deal)

MS #3965 Dementia occurring over a 32-year follow-up attributable to hypertension observed at different ages: Implications for dementia prevention (Jason Smith)

**11.a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data? \_\_\_\_ Yes ☒ No**

**11.b. If yes, is the proposal**

- ☐ A. primarily the result of an ancillary study (list number\* \_\_\_\_\_)  
☐ B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)\* 2014.38; 2018.07 )

\*ancillary studies are listed by number <https://sites.csc.unc.edu/aric/approved-ancillary-studies>

**12a. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.**

**12b. The NIH instituted a Public Access Policy in April, 2008** which ensures that the public has access to the published results of NIH funded research. It is **your responsibility to upload manuscripts to PubMed Central** whenever the journal does not and be in compliance with this policy. Four files about the public access policy from <http://publicaccess.nih.gov/> are posted in <http://www.csc.unc.edu/aric/index.php>, under Publications, Policies & Forms. [http://publicaccess.nih.gov/submit\\_process\\_journals.htm](http://publicaccess.nih.gov/submit_process_journals.htm) shows you which journals automatically upload articles to PubMed central.

## REFERENCES

1. Loughrey DG, Kelly ME, Kelley GA, Brennan S, Lawlor BA. Association of Age-Related Hearing Loss With Cognitive Function, Cognitive Impairment, and Dementia: A Systematic Review and Meta-analysis. *JAMA Otolaryngol Head Neck Surg.* 2018;144(2):115-126.
2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet.* 2020;396(10248):413-446.
3. Nianogo RA, Rosenwohl-Mack A, Yaffe K, Carrasco A, Hoffmann CM, Barnes DE. Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US. *JAMA Neurol.* 2022;79(6):584-591.
4. Liang Z, Li A, Xu Y, Qian X, Gao X. Hearing Loss and Dementia: A Meta-Analysis of Prospective Cohort Studies. *Front Aging Neurosci.* 2021;13:695117.
5. Kamil RJ, Genther DJ, Lin FR. Factors associated with the accuracy of subjective assessments of hearing impairment. *Ear Hear.* 2015;36(1):164-167.
6. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. *Am J Public Health.* 1998;88(1):15-19.
7. Benichou J. A review of adjusted estimators of attributable risk. *Stat Methods Med Res.* 2001;10(3):195-216.
8. Darrow LA, Steenland NK. Confounding and Bias in the Attributable Fraction. *Epidemiology.* 2011;22(1).
9. Knopman DS, Gottesman RF, Sharrett AR, et al. Mild Cognitive Impairment and Dementia Prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). *Alzheimers Dement (Amst).* 2016;2:1-11.
10. Gottesman RF, Albert MS, Alonso A, et al. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. *JAMA Neurol.* 2017;74(10):1246-1254.
11. Shukla A, Reed NS, Armstrong NM, Lin FR, Deal JA, Goman AM. Hearing Loss, Hearing Aid Use, and Depressive Symptoms in Older Adults-Findings from the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). *The journals of gerontology Series B, Psychological sciences and social sciences.* 2021;76(3):518-523.